BRENTUXIMAB VEDOTIN
brentuximab vedotin 50 mg injection, 1 vial
BRENTUXIMAB VEDOTIN (12632W)
12632W
Manner of administration:Injection
Restriction
Indication: CD30 positive peripheral T-cell lymphoma, non-cutaneous type
Treatment phase: Continuing treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 200 mg | # of repeats: 1 | DPMA: $18,073.54 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Adcetris
(brentuximab vedotin 50 mg injection, 1 vial)
|
||||